{"name":"Alza Corporation, DE, USA","slug":"alza-corporation-de-usa","ticker":"","exchange":"","domain":"","description":"","hq":"Mountain View","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"OROS Hydromorphone HCI","genericName":"OROS Hydromorphone HCI","slug":"oros-hydromorphone-hci","indication":"Moderate to severe chronic pain requiring continuous opioid therapy","status":"phase_3"},{"name":"OROS hydromorphone HCL ; Morphine sulfate","genericName":"OROS hydromorphone HCL ; Morphine sulfate","slug":"oros-hydromorphone-hcl-morphine-sulfate","indication":"Moderate to severe chronic pain requiring continuous opioid therapy","status":"phase_3"},{"name":"OROS hydromorphone HCL ; OxyContin","genericName":"OROS hydromorphone HCL ; OxyContin","slug":"oros-hydromorphone-hcl-oxycontin","indication":"Management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"OROS® oxybutynin","genericName":"OROS® oxybutynin","slug":"oros-oxybutynin","indication":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency","status":"phase_3"},{"name":"OROS® oxybutynin or Ditropan®","genericName":"OROS® oxybutynin or Ditropan®","slug":"oros-oxybutynin-or-ditropan","indication":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency","status":"phase_3"},{"name":"Ritalin (methylphenidate)","genericName":"Ritalin (methylphenidate)","slug":"ritalin-methylphenidate","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"E-TRANS Fentanyl hydrochloride; Morphine","genericName":"E-TRANS Fentanyl hydrochloride; Morphine","slug":"e-trans-fentanyl-hydrochloride-morphine","indication":"Chronic pain management","status":"phase_3"}]}],"pipeline":[{"name":"OROS Hydromorphone HCI","genericName":"OROS Hydromorphone HCI","slug":"oros-hydromorphone-hci","phase":"phase_3","mechanism":"OROS Hydromorphone HCI is an extended-release opioid agonist that binds to mu-opioid receptors in the central nervous system to provide sustained pain relief.","indications":["Moderate to severe chronic pain requiring continuous opioid therapy"],"catalyst":""},{"name":"E-TRANS Fentanyl hydrochloride; Morphine","genericName":"E-TRANS Fentanyl hydrochloride; Morphine","slug":"e-trans-fentanyl-hydrochloride-morphine","phase":"phase_3","mechanism":"E-TRANS is a transdermal delivery system that provides sustained release of fentanyl and morphine, potent opioid agonists that bind to mu opioid receptors in the central nervous system to produce analgesia and pain relief.","indications":["Chronic pain management","Cancer pain"],"catalyst":""},{"name":"OROS hydromorphone HCL ; Morphine sulfate","genericName":"OROS hydromorphone HCL ; Morphine sulfate","slug":"oros-hydromorphone-hcl-morphine-sulfate","phase":"phase_3","mechanism":"OROS hydromorphone HCl is an extended-release opioid agonist that binds to mu opioid receptors in the central nervous system to provide prolonged pain relief.","indications":["Moderate to severe chronic pain requiring continuous opioid therapy"],"catalyst":""},{"name":"OROS hydromorphone HCL ; OxyContin","genericName":"OROS hydromorphone HCL ; OxyContin","slug":"oros-hydromorphone-hcl-oxycontin","phase":"phase_3","mechanism":"OROS hydromorphone HCL is a long-acting opioid analgesic that works by binding to opioid receptors in the brain, spinal cord, and other areas of the body.","indications":["Management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time"],"catalyst":""},{"name":"OROS® oxybutynin","genericName":"OROS® oxybutynin","slug":"oros-oxybutynin","phase":"phase_3","mechanism":"OROS oxybutynin is an anticholinergic agent that blocks muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","indications":["Overactive bladder with symptoms of urge incontinence, urgency, and frequency","Neurogenic detrusor overactivity in spinal cord injury patients"],"catalyst":""},{"name":"OROS® oxybutynin or Ditropan®","genericName":"OROS® oxybutynin or Ditropan®","slug":"oros-oxybutynin-or-ditropan","phase":"phase_3","mechanism":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","indications":["Overactive bladder with symptoms of urge incontinence, urgency, and frequency","Neurogenic detrusor overactivity in spinal cord injury patients"],"catalyst":""},{"name":"Ritalin (methylphenidate)","genericName":"Ritalin (methylphenidate)","slug":"ritalin-methylphenidate","phase":"phase_3","mechanism":"Ritalin (methylphenidate) works by increasing the levels of dopamine and norepinephrine in the brain, which helps to improve attention and reduce impulsivity.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQd1BSdGNva0tpWmhrQ0lfb0F3M3JGX093cTRZczBURnhXVmkwU1VFenJVcndjM1o5X1dVc3YtekpmczhDdHVTSUJ1V3BGdUpvNHdyZElfZjh3V291MEhiYWFqNHp6NDRJZE12ZmRIR1EtajFndjJEUjVXYjJQNENUcnlvZ3FQR21mRHI5Uk9hNFc4U0RZc0Z1bmNB?oc=5","date":"2026-04-07","type":"regulatory","source":"openPR.com","summary":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight - openPR.com","headline":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOV2ZMQ1VlejBOaHJtUEt2d3VoSXYxc1AzOXg5V3RaQ0lXc2Q3Zm8xRXo0YzFUVm1YdXNyY25rM0dSaGNCQUxCelZRaGZYLTJ1aFJ5UzNRaDJRLVBSeFE5YVFvb0lncjY5WjBMV1dKX1RPa3JiQmQ2bkpGdXh6S0NMNzlhbFp2MjVsb1NVNUdYaVlMQ1JPSGVpTUhKVTBSSHl0OXdZbw?oc=5","date":"2026-02-03","type":"pipeline","source":"Stock Titan","summary":"Veteran biotech commercial leader Michael P. Miller joins Rigel board - Stock Titan","headline":"Veteran biotech commercial leader Michael P. Miller joins Rigel board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQb2NSMEVuTExDWUFnZVZHVUZYdDdPMzBqTzVxRXlPOEpWWWQxNFo2NC1jdnJKZmJUeXA5OHloNzVHZTQ2ZngtNkwzcHhNU3BvQzZVRlpHWVYtc01lNnNiZ3RXLU5SSGJMX2laMGxnV3V4R3ZMUGFKTkRseE1VVzZwNGZwX1F5ZEVJNkEzX1gyMEFXUQ?oc=5","date":"2024-10-20","type":"pipeline","source":"Legacy","summary":"Ernest Mario Obituary (1938 - 2024) - Key West, FL - The News & Observer - Legacy","headline":"Ernest Mario Obituary (1938 - 2024) - Key West, FL - The News & Observer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPYnZZTlJaRXkxM1dNVmtydEZHVWdzcXFHRjFlbE1BNXRNWjF2d1JSazh2R2ZoR1NzQnptM2NqZVMxZHlWbTNNR19qQlZpeEVndWgydmlQV3hOdDZWUjBrZzZsYzVid0MwTlowN3dfSGZSbEJHdnVYMHNsLW5IeEFOQnNicnUyQ2c?oc=5","date":"2019-04-28","type":"pipeline","source":"chemeurope.com","summary":"List_of_pharmaceutical_companies - chemeurope.com","headline":"List_of_pharmaceutical_companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE5HNlJSdnhqR2FLN0NGaHM0WDUxT3VPRjJtR3ZXM1ViN3lPWTZQcXNLZGt1aWdsN2JCR0xSalVLOV9FRFpucV9ySWxXN3p1SHJiSG5KQmphNzRTbVM0bjBfaUdianFSb2k0ZXBR?oc=5","date":"2019-04-03","type":"pipeline","source":"Pharmafile","summary":"Janssen closes plant in California, 49 positions axed - Pharmafile","headline":"Janssen closes plant in California, 49 positions axed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5DekpYbTZoUXBQc2p0SlF1U1NsZXZSR3E5R0Qwd0RqRm9ieTR0d3Z2TXVSeVBrUkxnRHgwc1NSNm1LY2tHbnp6d1dhZ25pZVhiclp4YkNpV2RXVmtaTnhtTUc4VTVGdGVXWEZTV250UWlwQzBncG5pcA?oc=5","date":"2018-02-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Fentanyl: where did it all go wrong? - Pharmaceutical Technology","headline":"Fentanyl: where did it all go wrong?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFAxQ21vMEZHRGxXTzhqX1Fja2RvZ0JfM3NhMEJ2Uy1JUDNHdlFPdV8yOERQVmE2dzQ3RklHbGVYX0lqWENIWTUyM3FhNW1qVi00S1ppV0l6VElKNkhhdUdrai1XRnVwa1FQYkE?oc=5","date":"2007-11-07","type":"pipeline","source":"Wiley Online Library","summary":"Professor William I. Higuchi: Teacher and scientist - Ho - 2008 - Journal of Pharmaceutical Sciences - Wiley Online Library","headline":"Professor William I. Higuchi: Teacher and scientist - Ho - 2008 - Journal of Pharmaceutical Sciences","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":7},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}